# Lung-MAP S1400K: c-MET Positive

> **NCT03574753** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 28 (actual)

## Conditions studied

- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC V7

## Interventions

- **DRUG:** ABBV-399

## Key facts

- **NCT ID:** NCT03574753
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-16
- **Primary completion:** 2019-12-21
- **Final completion:** 2021-07-30
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2021-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03574753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03574753, "Lung-MAP S1400K: c-MET Positive". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03574753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*